Zydus Cadila has completed patient enrolment in DREAM-ND and DREAM-D Phase III trials of Desidustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for treatment of anaemia in patients with Chronic Kidney Disease (CKD).
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis. This Phase II study is a multicentre (68 sites), randomized, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the treatment of anaemia in patients with chronic kidney disease (CKD) who are not on dialysis.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1516.95 |
Dr. Reddys Lab | 5928.80 |
Cipla | 1353.55 |
Zydus Lifesciences | 919.55 |
Lupin | 1555.65 |
View more.. |